生物医学,以启动对AI型哮喘药物GB-0895进行全球第三阶段试验的生物医学,旨在减少恶化并改进肺功能。 Biomedicines to launch global Phase 3 trials for AI-designed asthma drug GB-0895, aiming to reduce exacerbations and improve lung function.

产生:Bio Medices已宣布计划启动全球第3阶段的GB-0895临床试验,这是一项AI设计的长效抗体,针对治疗严重哮喘的TSLP。 Generate:Biomedicines has announced plans to launch global Phase 3 clinical trials for GB-0895, an AI-designed, long-acting antibody targeting TSLP for treating severe asthma. 试验将评价该药物在减少哮喘病恶化和改善肺功能方面的安全和功效。 The trial will evaluate the drug’s safety and efficacy in reducing asthma exacerbations and improving lung function. 预计今后几年将取得结果,可能获得批准,等待监管审查。 Results are expected in the coming years, with potential approval pending regulatory review.